A bottle that promises focus is easy to find. The label says attention, or memory, or clarity, and the ingredient list runs long: fish oil, a mineral or two, a plant extract you can't pronounce. What's harder to find is a straight answer about which of these has been tested in children, and how much it actually did.
Attention and working memory are the complaints that bring most families to a page like this. They turn up in autism and in ADHD, which overlap more often than not; by various estimates between about 30 and 60 percent of autistic children also meet the criteria for ADHD. That's why most of the usable evidence lives in the ADHD research, with a thinner autism literature next to it.
What follows is ingredient by ingredient: the results that held up, the ones that didn't, and the doses our own products can and can't reach.
Omega-3 nudges attention, and the nudge rides on EPA
Fish oil is the most studied supplement for attention, and the honest summary is a small effect, real but modest. A 2011 meta-analysis of ten trials in children with ADHD found an improvement of about a third of a standard deviation, and the benefit was larger in the formulas that carried more EPA rather than DHA (Bloch 2011, PMID 21961774). A later review landed in the same place and noted that children with ADHD tend to start with lower omega-3 levels to begin with (Chang 2018, PMID 28741625).
Set against that, the skeptics. The Cochrane reviewers, who hold the highest bar, judged the evidence low-certainty and the effect small or absent (Gillies 2023, PMID 37058600), and one well-run trial in children with moderate ADHD found nothing on its main measure (Cornu 2018, PMID 28993963). None of this is a stimulant. The medication effect is larger, which is why an ADHD diagnosis and how to treat it stay a conversation with your clinician, not a supplement decision.
In autism specifically the picture is mixed and weaker. One meta-analysis found a modest signal for hyperactivity (Cheng 2017, PMID 29042783); another, pooling different trials, found essentially nothing (Horvath 2017, PMID 28077731). EPA and DHA are structural fats in nerve-cell membranes, so there's a reason to keep them adequate. That's a smaller claim than fixing attention.
Iron and zinc help the children who were short of them
This is the part with the clearest logic and the biggest catch. Children with ADHD have, on average, lower iron stores than other children (Cortese 2012, PMID 23082739). In a trial of children whose ferritin sat below 30, twelve weeks of iron cut ADHD rating-scale scores by about eleven points against placebo (Konofal 2008, PMID 18054688). The dose that did it was 80 mg of ferrous sulfate a day, a therapeutic dose from a pharmacy, not the 3 mg tucked into a children's multivitamin. Those are different things, and it matters that nobody blurs them.
So the iron story is really a testing story. Ask for a ferritin level; if it comes back low, the first-line answer is a prescription iron product at a real dose, taken under supervision, with a repeat test to confirm. And give iron the respect it demands: swallowing a bottle of iron tablets is one of the leading causes of fatal poisoning in young children, so any iron in the house belongs locked away and out of reach.
Zinc runs on the same rails. The largest trial, in around 400 children, found that zinc sulfate lowered hyperactivity and impulsivity but not inattention, and the children who gained were mostly the ones who had started low (Bilici 2004, PMID 14687872). In well-nourished children who weren't short of zinc to begin with, the results were equivocal (Arnold 2011, PMID 21309695). Correcting a deficiency helps; topping up a child who is already replete mostly doesn't, and past about 40 mg a day zinc starts to compete with copper.
Phosphatidylserine has the cleanest small result, at a dose most products miss
Phosphatidylserine is a phospholipid that sits in neuronal membranes, and for its size it has the tidiest pediatric result in this whole area. In a two-month trial, children with ADHD who took 200 mg a day improved both on ADHD symptoms and on a short-term auditory working-memory task (Hirayama 2014, PMID 23495677). A separate trial paired phosphatidylserine with omega-3 and reported symptom improvement with good tolerability (Manor 2012, PMID 21807480).
The number to hold onto is 200 mg a day. Most supplements that contain phosphatidylserine deliver far less, and the few that reach a near-trial dose tend to bundle it with other actives the trials didn't use. That makes the label worth reading closely.
A broad multivitamin beat placebo for the clinician, not for the parents
Rather than one nutrient, the MADDY trial tested a broad vitamin and mineral formula in 135 children with ADHD, and the result split in an instructive way. Clinicians who didn't know who got what rated 54 percent of the supplement group as improved, against 18 percent on placebo, close to a threefold difference (Johnstone 2022, PMID 34303786). The parents' own primary rating, though, showed no significant gap. An earlier programme of work found that the children who responded were partly predicted by their nutrient status at the start (Rucklidge 2019, PMID 30217770).
Read alongside iron and zinc, the multivitamin evidence points the same way: fill the gaps a selective eater is likely to have, and look for the gains where there were gaps to fill.
Magnesium L-threonate looks good in adults, and only in adults
Magnesium L-threonate is a form built to raise magnesium in the brain rather than only in the blood. In older adults with cognitive complaints it improved test scores over a few months (Liu 2016, PMID 26519439), and a later trial in healthy adults pointed the same way (Zhang 2022, PMID 36558392). That is a genuine adult signal.
No one has tested it in children, in ADHD or in autism. For a child, then, it stays a maybe resting on adult data, a weaker footing than most of what sits above it.
What we leave out, and the vitamin D result we don't count
Some popular focus ingredients earn shelf space from studies that don't apply here. Huperzine A improves cognition in adults with dementia (Xing 2014, PMID 24639880), but it has no pediatric or ADHD data, and it is an acetylcholinesterase inhibitor with cholinergic side effects and a seizure-threshold concern that carries more weight in a group with a higher rate of epilepsy. Ginkgo has been tried in ADHD and came out worse than methylphenidate (Salehi 2010, PMID 19815048), while bringing its own bleeding and seizure cautions. The dopamine-precursor sprays and other stimulant-style blends have no controlled trial in children at all, so we leave them off.
Vitamin D deserves its own line, because families ask. There was a positive trial of vitamin D for autism, and it was retracted in 2019 after its data didn't hold up; we don't cite it or count it. The autism trial that survives scrutiny found no cognitive or behavioural effect (Kerley 2017, PMID 28626020). Correcting a documented vitamin D deficiency is worth doing on its own merits, but a focus claim built on vitamin D isn't supported.
How this shapes our protocol
Our Focus & Clarity protocol is built from the two ingredients that carry the best evidence we can actually deliver, sitting on a base that corrects the gaps. For an adult, that is Omega-3 Mini (dosed to favour EPA) and Magnesium L-Threonate once a day; the once-a-day part matters, because a second scoop would push total magnesium past the daily ceiling we hold to. A phosphatidylserine option, Spectrum BDNF Support, covers the working-memory angle, though its label needs reading: the scoop gives 150 mg, under the 200 mg that was studied; it also carries acetyl-L-carnitine and alpha-GPC that the trials didn't use; it contains soy and bears a Prop 65 notice; and it takes the place of the magnesium powder rather than adding to it, since two magnesium sources would breach the cap. Its name points at BDNF, which nothing in the formula is shown to raise, so judge it by its actual ingredients. An adult multivitamin, Formula C, is optional, with a caution that its B6 sits above the level we would want in a child.
For a child, and only with a clinician directing it, the protocol is the children's multivitamin (Spectrum Formula + Iron) plus Omega-3 Mini, with Spectrum Neurotransmitter Support (ages four and up) as an option whose every active sits well below its trial dose. You can read the whole thing at /protocols/focus-and-clarity.
The limits are worth saying plainly. Most of this evidence comes from adults or from children with ADHD rather than autism; no one has tested this combination as a combination; and where our doses differ from the trials, they run lower, from the 150 mg of phosphatidylserine against a studied 200 to the 3 mg of iron that is nowhere near a treatment dose. Think of these as supports for a family already working with a clinician on the things that move attention most, not a replacement for them.
Sources
- Bloch MH, Qawasmi A. 2011. J Am Acad Child Adolesc Psychiatry. PMID 21961774
- Chang JP, et al. 2018. Neuropsychopharmacology. PMID 28741625
- Gillies D, et al. 2023. Cochrane Database of Systematic Reviews. PMID 37058600
- Cornu C, et al. 2018. European Child & Adolescent Psychiatry. PMID 28993963
- Cheng YS, et al. 2017. Neuropsychiatric Disease and Treatment. PMID 29042783
- Horvath A, et al. 2017. Journal of Nutrition. PMID 28077731
- Cortese S, et al. 2012. Expert Review of Neurotherapeutics. PMID 23082739
- Konofal E, et al. 2008. Pediatric Neurology. PMID 18054688
- Bilici M, et al. 2004. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 14687872
- Arnold LE, et al. 2011. Journal of Child and Adolescent Psychopharmacology. PMID 21309695
- Hirayama S, et al. 2014. Journal of Human Nutrition and Dietetics. PMID 23495677
- Manor I, et al. 2012. European Psychiatry. PMID 21807480
- Johnstone JM, et al. 2022. Journal of the American Academy of Child & Adolescent Psychiatry. PMID 34303786
- Rucklidge JJ, et al. 2019. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 30217770
- Liu G, et al. 2016. Journal of Alzheimer's Disease. PMID 26519439
- Zhang C, et al. 2022. Nutrients. PMID 36558392
- Xing SH, et al. 2014. Evidence-Based Complementary and Alternative Medicine. PMID 24639880
- Salehi B, et al. 2010. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 19815048
- Kerley CP, et al. 2017. Archives of Disease in Childhood. PMID 28626020